More on Sequenom's (SQNM) Q2: CMM diagnostics services revenues come in at $24.5M. The company...

|By:, SA News Editor

More on Sequenom's (SQNM) Q2: CMM diagnostics services revenues come in at $24.5M. The company says it (as well as competitors) "experienced delays in receipt of payments as a result of molecular diagnostics coding changes adopted by CMS, Medicaid and third party payors." Total tests accessioned rise 130% to 46,700 patient samples (38K MaterniT21 PLUS samples). Overall gross margin climbs 200 bps Y/Y. CFO Paul Maier says he is "disappointed by the delay in the collection of diagnostic segment revenues during the second quarter," but notes that collections should improve in H2. Update 4:39: Shares slide 25% AH. (PR)